A5085298680- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Platelet Disorders and Treatments
- Chronic Myeloid Leukemia Treatments
- Monoclonal and Polyclonal Antibodies Research
- Immunodeficiency and Autoimmune Disorders
- Blood groups and transfusion
- Autoimmune Bullous Skin Diseases
- Eosinophilic Disorders and Syndromes
- Lysosomal Storage Disorders Research
- Potassium and Related Disorders
- Parkinson's Disease Mechanisms and Treatments
- Systemic Lupus Erythematosus Research
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Helicobacter pylori-related gastroenterology studies
- Hematological disorders and diagnostics
- Clinical Laboratory Practices and Quality Control
- Cellular transport and secretion
- Protein Tyrosine Phosphatases
- Gastrointestinal disorders and treatments
- Vitamin K Research Studies
- Autoimmune and Inflammatory Disorders Research
- Cell Adhesion Molecules Research
University of California, San Francisco
2024
Arizona Oncology
2014-2023
University of Arizona
2011
Banner - University Medical Center Tucson
2011
Dana-Farber Cancer Institute
2006
University of Wisconsin–Madison
2006
St. Joseph's Hospital
2005
Cornell University
1985
North Shore University Hospital
1985
Jewish Hospital
1973-1976
Although thrombocytosis is a very common finding after splenectomy, the thromboembolic risk of postsplenectomy has not been clarified. To our knowledge, this retrospective study 318 patients without myeloproliferative disorders who underwent splenectomy largest its type. Thrombocytosis developed in 75% patients. No substantial increase incidence thromboembolism was detected with thrombocytosis.
Mutations in GBA1 gene that encodes lysosomal glucocerebrosidase result Type 1 Gaucher Disease (GD), the commonest storage disorder; most prevalent disease mutation is N370S. We investigated heterogeneity and natural course of N370S GD 403 patients. Demographic, clinical, genetic characteristics at presentation were examined a cross-sectional study. In addition, relative risk (RR) cancer patients compared with age-, sex-, ethnic-group adjusted national rates was determined. Of patients, 54%...
The clinical and laboratory experience with the lupus anticoagulant was reviewed in 37 patients. anti-coagulant is thought to act by blocking activation of prothrombin activator comlex factors Xa, V, phospholipid. Although has been principally associated diseases immune origin, 14 present patients had disorders not be nature. Eighteen underwent twenty-one operative procedures only a single episode excessive bleeding. In author's experience, rare cause
Two randomized, double-blind, placebo-controlled studies demonstrated responses (≥50 000/μL) to fostamatinib in adults with long-standing immune thrombocytopenia (ITP). The long-term safety and efficacy of were evaluated a follow-on, open-label extension (OLE) study. Patients received double-blind the randomized trials, responders continued same dose, 100 150 mg BID, OLE Nonresponders BID for 4 weeks could escalate at week 4. Endpoints included stable response, platelet count ≥50 000/μL 4/6...
Abstract Fostamatinib demonstrated efficacy in phase 3 trials of adults with immune thrombocytopenia (ITP). Post hoc analysis compared patients who received fostamatinib as second‐line therapy (after steroids ± immunoglobulins) versus third‐or‐later‐line ≥2 prior lines including a agent). Platelet responses ≥50 000/µl were observed 25/32 (78%) and 54/113 (48%) patients. Bleeding events less frequent (28%) (45%) Responses once achieved tended to be durable both groups. The safety profile was...
Although anemia has not been widely appreciated as a complication of primary hyperparathyroidism, 5.1% the individuals with this disorder seen at Massachusetts General Hospital since 1962 had normochromic, normocytic that could be related to blood loss,a deficiency state, or uremia. The anemic group more advanced bone disease and higher levels serum calcium, alkaline phosphatase, parathyroid hormone than nonanemic group. Results marrow biopsies performed in five patients showed variable...
BACKGROUND Patients with myeloproliferative neoplasms (MPNs) experience a high persistence, prevalence, and severity of fatigue. There is currently only limited information regarding factors that contribute to fatigue in patients MPNs. METHODS A 70‐item, Internet‐based survey was developed by MPN investigators patients/advocates hosted the Mayo Clinic Survey Research Center. RESULTS Fatigue found be prevalent severe among international respondents (1788 respondents). Higher body mass index (...
Abstract Patients with relapsed warm antibody autoimmune hemolytic anemia (wAIHA) have limited treatment options. Fostamatinib is a potent, orally administered spleen tyrosine kinase inhibitor approved in the United States and Europe for of adults chronic immune thrombocytopenia (ITP). This phase 2 study evaluated response to fostamatinib, at 150 mg BID or without food wAIHA active hemolysis hemoglobin (Hgb) <10 g/dL who had failed least one prior treatment. Hemoglobin levels safety...
7083 Background: Early phase 1/2 trials with GA101 in CLL demonstrated single-agent activity suggestion of a dose response. GAGE (NCT01414205) is multicenter, randomized study that evaluated at 2 doses patients (pts) symptomatic, untreated CLL. Methods: Randomization 80 pts intact organ function and ECOG PS <3 were stratified based on Rai stage (1–2 vs 3–4) tumor mass (single lesion by CT scan, <5 cm ≥5 cm): 1,000 mg (100 IV d1, 900 d2, 1000 d8, d15 cycle 1; d1 cycles 2–8) or 2000 d3, 2,000...
Abstract Background Philadelphia chromosome negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia, polycythemia vera, and myelofibrosis, have severe function‐limiting symptom burden that is experienced by the majority of patients. Previous studies suggested depression may be present in over a quarter MPN patients, but to date no evaluated relationship between other variables such as symptoms. Methods A 70‐item internet based survey regarding fatigue mood symptoms...
7523 Background: Alemtuzumab (Campath-1H) is a fully humanized anti-CD52 antibody used to treat B and T-cell disorders. CD52 widely expressed on bone marrow lymphoplasmacytic cells growth supporting mast in patients with lymphoma (LPL), including Waldenstrom’s macroglobulinemia (WM). We therefore examined the activity of alemtuzumab LPL. Methods: 28 LPL, 27 WM were enrolled this multicenter study. 23 previously treated. Median age was 60 (range 33–75 years), median prior therapies 2 0–5),...
7007 Background: Spleen tyrosine kinase (Syk) is a mediator of B-cell receptor signaling in normal and transformed B-cells. GS-9973 an orally bioavailable, selective inhibitor Syk (Kd 7.6 nM, no other < 100 nM). Methods: This Phase 2 trial enrolled 44 subjects with CLL treated 800 mg BID. Tumor imaging occurred at weeks 8, 16, 24 then every 12. Response was independently evaluated according to Hallek 2008 as modified by Cheson 2012. plasma levels were obtained concurrently chemo/cytokine...
Iron deficiency anemia without evidence for blood loss can present a diagnostic challenge. Proton pump inhibitors have been associated with iron many years, yet the relationship between two until recently was not fully understood. Treatment recommendations are lacking.This study evaluated 43 deficient patients who were taking proton inhibitors, 41 of whom unresponsive to oral iron, and no etiology could be found. Two had hereditary hemochromatosis never treated iron.Forty-three inhibitor...
After an 8-year period of aplastic anemia following chloramphenicol therapy, a 39-year-old woman developed subleukemic acute myelogenous leukemia, and she died with Pseudomonas sepsis 18 months later. Autopsy demonstrated leukemic cellular thrombi that partially or completely occluded many small pulmonary arteries, arterioles, veins. Scattered among the cells in were hemosiderotic histiocytes reflecting transfusional hemosiderosis. The staining characteristics, esterase activity, electron...